Search results
'Dramatic' Phase 2 Results for Survodutide in MASH, Fibrosis
Medscape· 2 days agoSurvodutide, a dual agonist that targets glucagon and glucagon-like peptide 1 receptors, led to a...
Edible Carbon Beads Can Reduce Cirrhosis Liver Disease By Restoring Gut Microbiome
GoodNewsNetwork· 5 days agoInnovative carbon beads, invented by researchers at University College London, reduce bad bacteria...
Medical Breakthroughs: Man overcomes fatty liver disease
KRGV Rio Grande Valley· 6 days agoOne man’s post-retirement plans were cut short when doctors told him he had end stage liver disease....
Health Care Roundup: Market Talk
The Wall Street Journal· 2 days agoNEWSPLUS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0829 ET...
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug
Reuters via AOL· 3 days ago(Reuters) -The U.S. Food and Drug Administration granted accelerated approval to French drugmakers...
16 small changes to your diet that will help you live longer
The Telegraph via Yahoo News· 22 hours agoWhen you picture yourself in old age, you may assume you’ll be frail, have limited mobility and...
Tirzepatide Shows Improvements in MASH Resolution, Fibrosis
Medscape· 4 days agoEncouraging phase 2 results of tirzepatide in the resolution of MASH and improvement in fibrosis...
US FDA grants accelerated approval to Genfit and Ipsen’s liver disease drug
WSAU Wausau· 3 days ago(Reuters) -The U.S. Food and Drug Administration has granted accelerated approval French drugmakers...
SCOTUS abortion pill ruling leaves advocates eyeing future legal battles
NBC Chicago· 3 hours agoMany abortion rights supporters are considering Thursday a narrow win after learning the most...
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL...
The Herald Journal· 4 days agoLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late breaking oral presentation at the European Association ...